CD274 and neoplasm: In preclinical models, treatment with 177Lu–LNC1004 has been shown to induce a transient upregulation of PD‐L1 expression on tumor cells, thereby sensitizing tumors to ICI therapy and enhancing overall antitumor efficacy [468].